Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs Novartis AG — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $13.5, while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while KraneShares Hang Seng TECH Index ETF pays none, and Novartis AG is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.
| KTEC | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $19.51 | $168.62 |
52-Week Low | $12.00 | $118.55 |
Market Cap | — | $298.18B |
Enterprise Value | — | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC trades at $13.78, up 1.47% today, with a bullish technical signal driven by moving averages. Support and resistance cluster at $14, indicating a critical price zone. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights China's AI competition as a potential catalyst for tech ETFs like KTEC.
The stock's outlook hinges on AI sector momentum, but risks include reliance on thematic trends and lack of disclosed financials. Upside depends on broader tech ETF inflows, while volatility from geopolitical or market shifts poses a near-term challenge.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
